PLI Scheme for Promotion Of Domestic Manufacturing of Critical KSMS/Drug Intermediates and APIs

  • IASbaba
  • April 17, 2021
  • 0
UPSC Articles
Print Friendly, PDF & Email

PLI Scheme for Promotion Of Domestic Manufacturing of Critical KSMS/Drug Intermediates and APIs

Part of: GS Prelims and GS-III – Economy 

In news

Key takeaways 

  • The setting up of these 16 plants will lead to investment of Rs.348.70 crore and employment generation of about 3,042 by the companies.
  • The commercial production shall commence from 1st April, 2023 onward.
  • The scheme has been launched by the Department of Pharmaceuticals for promotion of domestic manufacturing of KSMs/APIs.
  • This will be achieved by setting up greenfield plants with minimum domestic value addition 

Do you know? 

  • The Indian pharmaceutical industry is the 3rd largest in the world by volume.
  • However, India is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. 
  • In some specific bulk drugs, the import dependence is 80 to 100%.

Search now.....

Sign Up To Receive Regular Updates